Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort

Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner. Here, we report the detection of EGFR L792 mutations, a non-covalent mechanism of osimertinib resistance, using Guardant360 cfDNA...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Exp Hematol Oncol
Hoofdauteurs: Fairclough, Stephen R., Kiedrowski, Lesli A., Lin, Jessica J., Zelichov, Ori, Tarcic, Gabi, Stinchcombe, Thomas E., Odegaard, Justin I., Lanman, Richard B., Shaw, Alice T., Nagy, Rebecca J.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2019
Onderwerpen:
Rapid Communication
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6788107/
https://ncbi.nlm.nih.gov/pubmed/31632838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-019-0148-7
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items